Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7368877 | 0.99 | SLC6A4 (0.44) | SLC6A4SLC6A3SLC6A2CHRM2CHRM1 | |
| SCHEMBL4837226 | 0.98 | SLC6A4 (0.45) | SLC6A4SLC6A3SLC6A2CHRM2CHRM1 | |
| SCHEMBL4831862 | 0.97 | SLC6A4 (0.44) | SLC6A4SLC6A3SLC6A2CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL8529249 | 0.97 | SLC6A4 (0.44) | SLC6A4SLC6A3SLC6A2CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL7374494 | 0.96 | SLC6A4 (0.43) | SLC6A4SLC6A3SLC6A2CHRM2CHRM1 | |
| Fumaric Acid SCHEMBL8846221 | 0.94 | SLC6A4 (0.40) | SLC6A4SLC6A3SLC6A2CHRM2CHRM1 | |
| Fumaric Acid SCHEMBL8846236 | 0.94 | SLC6A4 (0.40) | SLC6A4SLC6A3SLC6A2CHRM2CHRM1 | |
| SCHEMBL4834581 | 0.93 | SLC6A4 (0.47) | SLC6A4SLC6A3SLC6A2CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL7372762 | 0.92 | SLC6A4 (0.46) | SLC6A4SLC6A3SLC6A2CHRM2CHRM1 | |
| Citric Acid SCHEMBL7367089 | 0.89 | ACLY (0.38) | SLC6A4SLC6A3SLC6A2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407990-B2 | Therapeutic Agents | KNOLL GMBH (DE) | 2008-08-05 | — | — | US | claimed |
| US-20070129445-A1 | Therapeutic Agents | KNOLL GMBH (DE) | 2007-06-07 | — | — | US | claimed |
| US-6974840-B1 | Therapeutic agents | KNOLL GMBH (DE) | 2005-12-13 | — | — | US | claimed |
| US-20050182141-A1 | Therapeutic agents | LUSCOMBE GRAHAM P (GB) | 2005-08-18 | — | — | US | claimed |
| EP-1198229-A1 | THERAPEUTIC AGENTS | Knoll GmbH (DE) | 2002-04-24 | — | — | EP | claimed |
| WO-2001001979-A1 | THERAPEUTIC AGENTS | KNOLL GMBH (DE) | 2001-01-11 | — | — | WO | claimed |
| EP-0715620-B1 | 1-ARYLCYCLOALKYL SULPHIDES, SULPHOXIDES AND SULPHONES FOR THE TREATMENT OF DEPRESSION, ANXIETY AND PARKINSON'S DISEASE | KNOLL AG (DE) | 1998-10-28 | — | — | EP | claimed |
| EP-0715620-A1 | 1-ARYLCYCLOALKYL SULPHIDES, SULPHOXIDES AND SULPHONES FOR THE TREATMENT OF DEPRESSION, ANXIETY AND PARKINSON'S DISEASE | Knoll AG (DE) | 1996-06-12 | — | — | EP | claimed |
| WO-1994026704-A1 | 1-ARYLCYCLOALKYL SULPHIDES, SULPHOXIDES AND SULPHONES FOR THE TREATMENT OF DEPRESSION, ANXIETY AND PARKINSON'S DISEASE | THE BOOTS COMPANY PLC (GB) | 1994-11-24 | — | — | WO | claimed |
| US-9034852-B2 | Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-05-19 | — | — | US | disclosed |
| US-8796256-B2 | Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-α modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-05 | — | — | US | disclosed |
| EP-2536717-B1 | AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-04 | — | — | EP | disclosed |
| EP-2536716-B1 | AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-21 | — | — | EP | disclosed |
| US-8580832-B2 | Substituted phenoxy aminothiazolones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-11-12 | — | — | US | disclosed |
| EP-1198229-A1 | THERAPEUTIC AGENTS | Knoll GmbH (DE) | 2002-04-24 | — | — | EP | disclosed |
| WO-2001001979-A1 | THERAPEUTIC AGENTS | KNOLL GMBH (DE) | 2001-01-11 | — | — | WO | disclosed |
| EP-0715620-B1 | 1-ARYLCYCLOALKYL SULPHIDES, SULPHOXIDES AND SULPHONES FOR THE TREATMENT OF DEPRESSION, ANXIETY AND PARKINSON'S DISEASE | KNOLL AG (DE) | 1998-10-28 | — | — | EP | disclosed |
| US-5652271-A | ANTIDEPRESSANTS, NERVOUS SYSTEM DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 1997-07-29 | — | — | US | disclosed |
| EP-0715620-A1 | 1-ARYLCYCLOALKYL SULPHIDES, SULPHOXIDES AND SULPHONES FOR THE TREATMENT OF DEPRESSION, ANXIETY AND PARKINSON'S DISEASE | Knoll AG (DE) | 1996-06-12 | — | — | EP | disclosed |
| WO-1994026704-A1 | 1-ARYLCYCLOALKYL SULPHIDES, SULPHOXIDES AND SULPHONES FOR THE TREATMENT OF DEPRESSION, ANXIETY AND PARKINSON'S DISEASE | THE BOOTS COMPANY PLC (GB) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129445-A1 | Therapeutic Agents | OPRM1, CNR1, SIGMAR1 | SLC6A4 189/4885SLC6A3 33/4885SLC6A2 112/4885 |
| US-20050182141-A1 | Therapeutic agents | OPRM1, CNR1, SIGMAR1 | SLC6A4 212/4885SLC6A3 34/4885SLC6A2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.